USE OF THROMBOPOIETIN RECEPTOR AGONISTS IN PERSISTENT THROMBOCYTOPENIA FOLLOWING CAR-T THERAPY AND ALLOGENEIC HSCT: REAL-LIFE EXPERIENCE (SIE 2026) - Oct 6, 2026 - Abstract #DP149; Pres time: Sep 22, 2026; 06:30 PM - 07:30 PM; Location: AREA POSTER; "No statistically signifi- cant differences were found between the two drugs in terms of mean peak platelet count (68×10⁹/L in the Eltrombopag group and 56×10⁹/L in the Avatrombopag group, p=0.62), increase from nadir (63×10⁹/L and 52×10⁹/L, p = 0.55) or duration of treatment (95 vs 74 days; p=0.41).The results confirm the efficacy of TPO-RAs in promoting platelet recov- ery. Although Avatrombopag appears to be associated with a more rapid response in the CAR-T setting, both drugs have proven to be effective therapeutic options."
CAR T-Cell Therapy • Clinical • Bone Marrow Transplantation • Hematological Disorders • Thrombocytopenia
|
|
S. Indelicato; F. Plano; A. Pirrera; A. Crescimanno; R. Scalone; V. Polizzi; F. Porretto; V. Bonanno; V. Zammit; I. Abbene; M. Lanza Cariccio; F. Giammancheri; M. Musso
|